U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07499921) titled 'Clinical and BIOgical Analyses of RECtal Tumors' on March 24.
Brief Summary: Rectal cancer is a common cancer with an incidence of approximately 14,000 new cases per year in France. The survival rate is approximately 50% at 5 years, ranging from 90% for patients with localized rectal cancer to 18% for patients with metastases.
Surgery with local or complete exicion is the standard treatment for early stages. The implementation of Total Neoadjuvant Therapy (TNT) for locally advanced stages has led to a significant improvement in the prognosis for rectal cancer. The complete pathological response rate of aproximately 20% after TNT h...